Xendos study: Orlistat plus diet prevents, delays diabetes onset in obese patients

The FLOW trial was stopped early based on an interim analysis that found the study met the criteria for efficacy.

Although most older adults support Medicare coverage of medications for weight loss drugs, only one in three favor paying more in premiums for this coverage, finds University of Michigan survey.

Zepbound, which was approved last month to treat obesity, is now available in U.S. pharmacies.

Shortages are growing because of disruption caused natural disasters and ingredient supply issues, as well as increased demand for certain drugs.

Twice-daily danuglipron was being studied in a phase 2 study in adults with obesity. Pfizer is now conducting a pharmacokinetic study for a once-daily formulation.

A new survey finds that more people are using semaglutide and other GLP-1 therapies to lose less than 15 pounds.